Is Akero Therapeutics Stock a Good Investment?
Akero Therapeutics Investment Advice | AKRO |
- Examine Akero Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Akero Therapeutics' leadership team and their track record. Good management can help Akero Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Akero Therapeutics' business and its evolving consumer preferences.
- Compare Akero Therapeutics' performance and market position to its competitors. Analyze how Akero Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Akero Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Akero Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Akero Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Akero Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Akero Therapeutics Stock
Researching Akero Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 94.0% of the company shares are held by institutions such as insurance companies. The book value of Akero Therapeutics was presently reported as 10.61. The company has Price/Earnings To Growth (PEG) ratio of 0.93. Akero Therapeutics recorded a loss per share of 3.96. The entity had not issued any dividends in recent years.
To determine if Akero Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Akero Therapeutics' research are outlined below:
| Akero Therapeutics generated a negative expected return over the last 90 days | |
| Akero Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (151.76 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Akero Therapeutics currently holds about 180.72 M in cash with (145.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.81. | |
| Akero Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Akero Therapeutics Stock Price Down 8.6 percent Should You Sell |
Akero Therapeutics Quarterly Cash And Short Term Investments |
|
Akero Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Akero Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Akero Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Akero Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Akero Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-09 | 2024-06-30 | -0.9 | -0.81 | 0.09 | 10 | ||
2022-08-04 | 2022-06-30 | -0.86 | -0.77 | 0.09 | 10 | ||
2022-02-25 | 2021-12-31 | -0.82 | -0.93 | -0.11 | 13 | ||
2021-08-13 | 2021-06-30 | -0.72 | -0.83 | -0.11 | 15 | ||
2023-05-15 | 2023-03-31 | -0.67 | -0.55 | 0.12 | 17 | ||
2024-02-29 | 2023-12-31 | -0.86 | -0.99 | -0.13 | 15 | ||
2019-11-12 | 2019-09-30 | -0.43 | -0.56 | -0.13 | 30 | ||
2024-11-11 | 2024-09-30 | -0.9 | -1.05 | -0.15 | 16 |
Akero Therapeutics Target Price Consensus
Akero target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Akero Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Akero analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Akero stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Akero Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAkero Therapeutics Target Price Projection
Akero Therapeutics' current and average target prices are 25.14 and 48.27, respectively. The current price of Akero Therapeutics is the price at which Akero Therapeutics is currently trading. On the other hand, Akero Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Akero Therapeutics Market Quote on 18th of January 2025
Target Price
Analyst Consensus On Akero Therapeutics Target Price
Akero Therapeutics Analyst Ratings
Akero Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Akero Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Akero Therapeutics' financials, market performance, and future outlook by experienced professionals. Akero Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Akero Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Akero Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Akero Therapeutics backward and forwards among themselves. Akero Therapeutics' institutional investor refers to the entity that pools money to purchase Akero Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Boxer Capital Llc | 2024-09-30 | 1.7 M | Geode Capital Management, Llc | 2024-09-30 | 1.6 M | Redmile Group, Llc | 2024-09-30 | 1.4 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.3 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.3 M | Baker Bros Advisors Lp | 2024-09-30 | 1.1 M | Rock Springs Capital Management Lp | 2024-09-30 | 933.4 K | Logos Global Management Lp | 2024-09-30 | 800 K | Yiheng Capital Llc | 2024-09-30 | 758.8 K | Wellington Management Company Llp | 2024-09-30 | 7.9 M | Hhg Plc | 2024-09-30 | 7.1 M |
Akero Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.75 B.Market Cap |
|
Akero Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.28) | (0.29) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.33) | (0.31) |
Determining Akero Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Akero Therapeutics is a good buy. For example, gross profit margin measures Akero Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Akero Therapeutics' profitability and make more informed investment decisions.
Evaluate Akero Therapeutics' management efficiency
Akero Therapeutics has return on total asset (ROA) of (0.2317) % which means that it has lost $0.2317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.359) %, meaning that it created substantial loss on money invested by shareholders. Akero Therapeutics' management efficiency ratios could be used to measure how well Akero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of January 2025, Return On Tangible Assets is likely to drop to -0.25. In addition to that, Return On Capital Employed is likely to drop to -0.29. At this time, Akero Therapeutics' Total Assets are very stable compared to the past year. As of the 18th of January 2025, Net Tangible Assets is likely to grow to about 394.3 M, though Non Currrent Assets Other are likely to grow to (1.09).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.16 | 9.62 | |
| Tangible Book Value Per Share | 9.16 | 9.62 | |
| Enterprise Value Over EBITDA | (6.17) | (6.48) | |
| Price Book Value Ratio | 2.06 | 2.17 | |
| Enterprise Value Multiple | (6.17) | (6.48) | |
| Price Fair Value | 2.06 | 2.17 | |
| Enterprise Value | 1.7 B | 1.8 B |
The strategic initiatives led by Akero Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta (0.26) |
Basic technical analysis of Akero Stock
As of the 18th of January 2025, Akero Therapeutics shows the mean deviation of 2.7, and Risk Adjusted Performance of (0.04). Akero Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Akero Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akero Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akero Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akero Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akero Therapeutics' Outstanding Corporate Bonds
Akero Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Akero Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Akero bonds can be classified according to their maturity, which is the date when Akero Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Akero Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Akero Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.65) | |||
| Mean Deviation | 2.7 | |||
| Coefficient Of Variation | (1,657) | |||
| Standard Deviation | 3.46 | |||
| Variance | 12.0 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.30) | |||
| Treynor Ratio | (0.66) | |||
| Maximum Drawdown | 16.66 | |||
| Value At Risk | (5.05) | |||
| Potential Upside | 5.23 | |||
| Skewness | 0.2608 | |||
| Kurtosis | (0.07) |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.65) | |||
| Mean Deviation | 2.7 | |||
| Coefficient Of Variation | (1,657) | |||
| Standard Deviation | 3.46 | |||
| Variance | 12.0 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.30) | |||
| Treynor Ratio | (0.66) | |||
| Maximum Drawdown | 16.66 | |||
| Value At Risk | (5.05) | |||
| Potential Upside | 5.23 | |||
| Skewness | 0.2608 | |||
| Kurtosis | (0.07) |
Consider Akero Therapeutics' intraday indicators
Akero Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Akero Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Akero Therapeutics Corporate Filings
F4 | 10th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Akero Stock media impact
Far too much social signal, news, headlines, and media speculation about Akero Therapeutics that are available to investors today. That information is available publicly through Akero media outlets and privately through word of mouth or via Akero internal channels. However, regardless of the origin, that massive amount of Akero data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akero Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akero Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akero Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akero Therapeutics alpha.
Akero Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Akero Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Akero Therapeutics Corporate Management
| Timothy Rolph | CoFounder Officer | Profile | |
| Patrick Lamy | Senior Strategy | Profile | |
| Scott Gangloff | Chief Officer | Profile | |
| Catriona Yale | Executive Officer | Profile | |
| William JD | CFO, VP | Profile | |
| David JD | Vice Legal | Profile |
Already Invested in Akero Therapeutics?
The danger of trading Akero Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Akero Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Akero Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Akero Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Akero Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.